Christa Lawhorn
Adult Health · San Diego, CANPI 1083942734
Payments from drug & device makers
Across 110 payments — averaging $22.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$357
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$248
- Lilly USA, LLC$209
- AbbVie$202
- Novo Nordisk$159
- AstraZeneca$159
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,457100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 16 | $357 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $248 |
| Lilly USA, LLC | 9 | $209 |
| AbbVie | 7 | $202 |
| Novo Nordisk | 10 | $159 |
| AstraZeneca | 5 | $159 |
| Pfizer | 5 | $108 |
| Merck | 5 | $99 |
| Bayer | 4 | $88 |
| Amgen | 5 | $87 |
| Johnson & Johnson | 5 | $84 |
| Boehringer Ingelheim | 4 | $80 |
| Ardelyx, Inc. | 2 | $62 |
| Xeris Pharmaceuticals, Inc. | 3 | $61 |
| Sumitomo Pharma America, Inc. | 4 | $61 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
| Esperion Therapeutics, Inc. | 3 | $49 |
| Edwards Lifesciences | 2 | $44 |
| Lundbeck LLC | 2 | $40 |
| Acadia Pharmaceuticals Inc | 1 | $33 |
| Boston Scientific | 1 | $28 |
| Scpharmaceuticals Inc. | 1 | $27 |
| Eisai Inc. | 1 | $25 |
| Vivus LLC | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Shield Therapeutics Inc | 1 | $21 |
| Exact Sciences | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIFAXAN$124
How this compares
$2,457 in reported general payments places this provider in the 85th percentile of 785 adult health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 33 | $24,215 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $12,209 |
| UbrelvyUbrogepant | 11 | $10,904 |
| Spiriva RespimatTiotropium Bromide | 19 | $10,533 |
| MyrbetriqMirabegron | 13 | $10,404 |
| SteglatroErtugliflozin Pidolate | 12 | $4,103 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 56 | $1,874 |
| Ventolin HfaAlbuterol Sulfate | 16 | $1,674 |
| Atorvastatin Calcium | 104 | $1,033 |
| Diclofenac Sodium | 49 | $966 |
| Gabapentin | 94 | $802 |
| Levothyroxine Sodium | 107 | $786 |
| Fluticasone Propionate | 79 | $770 |
| Losartan Potassium | 55 | $653 |
| Paroxetine Hcl | 34 | $628 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $80 | $34,74852 claims |
| GSKTrelegy Ellipta | $357 | $12,20916 claims |
| AbbVieUbrelvy | $202 | $10,90411 claims |
| MerckSteglatro | $99 | $4,10312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 785 adult health providers in California.
Other adult health in San Diego
- Kimberly PodsadaSan Diego$78K
- Edith SavilleSan Diego$26K
- Alison AnthonySan Diego$7K
- Jessica ReyesSan Diego$5K
- Karolina FaysmanLos Angeles$1.1M
- Siok-Hian Tay-KelleyStanford$611K
- Linda BuckLos Angeles$170K
- Naomi PesynaAnaheim$141K
- Stacy GrissenEncinitas$82K
- Brenda PatrickSan Leandro$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.